The Risks of Unapproved GLP-1 Medications
Compounded versions of popular GLP-1 weight loss medications are flooding the market. While these drugs were initially intended to address supply shortages or specific patient needs, experts now warn that mass production has outpaced safety oversight. The FDA maintains that these unapproved versions do not undergo the same rigorous federal review for safety, quality, and effectiveness as branded counterparts like Ozempic.
The agency has issued public warnings regarding telehealth companies that misrepresent compounded drugs as identical to FDA-approved products. Regulators suggest consumers remain vigilant against providers offering deep discounts, lacking clear instructions, or failing to perform adequate medical screenings. Despite these warnings, the market for these unapproved alternatives continues to expand rapidly.
A Case Study in Medical Complications
Shawn Rose, a resident of Chicago, Illinois, sought weight loss medication through the telehealth platform Mochi Health after his insurance provider denied coverage for a traditional prescription. He paid a monthly fee to the San Francisco-based startup for shipments of compounded semaglutide. Rose reported the cost was roughly 75 percent lower than retail prices at a standard pharmacy.
After a dose increase, Rose fell severely ill. He spent time in the emergency room documenting his experience on social media, unable to retain food or water. He claimed he feared for his life during the medical episode. Further concerns emerged when Rose allegedly received vials without proper labeling from the company. Illinois state regulators are currently investigating his complaint against a Mochi Health nurse who reportedly responded to his emergency with a brief dismissal.
Regulatory Challenges and Industry Accountability
Evidence of systemic issues appeared in June when NBC Bay Area reported on Mochi Health and the closure of a Washington-based pharmacy. Investigators found that the facility permitted untrained assistants to compound GLP-1 drugs. Additional findings included unlicensed personnel processing prescriptions and the shipment of expired medications to patients. Neither Mochi Health nor the pharmacy involved responded to requests for comment regarding these findings.
Shabbir Imber Safdar, executive director of the Partnership for Safe Medicines, argues that these incidents reflect a broader industry pattern. He contends that many telehealth providers prioritize profit over patient safety. Since 2025, the Partnership has documented 50 state-level actions against compounders and 160 FDA warning letters sent to companies engaged in deceptive marketing practices.
The Path Forward for Patient Safety
Safdar suggests that current enforcement efforts fall short of protecting public health. He notes that while warning letters serve as an initial step, federal agencies have yet to refer many of these cases to the Department of Justice for prosecution. He argues that product recalls are necessary when deceptive sales tactics are proven.
The American Telemedicine Association maintains that these incidents are the result of bad actors rather than a failure of the telehealth delivery model. Still, regulators face pressure to increase oversight. Patients should verify the source of their medication and consult directly with licensed primary care physicians before purchasing compounded drugs online.